A 42-year-old man with a history of intravenous drug use presents with fever, malaise, and new-onset dyspnea for 2 weeks. On examination, he is febrile (39.2°C), has a new systolic murmur at the left sternal border, and Osler nodes on the fingertips. Chest X-ray shows multiple wedge-shaped opacities in both lungs. Blood cultures grow Staphylococcus aureus (methicillin-resistant). Transthoracic echocardiography shows a 18 mm vegetation on the tricuspid valve with moderate tricuspid regurgitation. Which of the following is the most appropriate antibiotic regimen?

Explanation

## Clinical Diagnosis & Organism This patient has **right-sided (tricuspid) IE** secondary to intravenous drug use (IVDU), with **methicillin-resistant Staphylococcus aureus (MRSA)**. **Key Point:** MRSA is the most common cause of IE in IVDU populations, followed by streptococci. The organism's resistance to beta-lactams mandates vancomycin-based therapy. ## Antibiotic Regimen for MRSA IE ### Standard Therapy **High-Yield:** For MRSA IE (native or prosthetic valve): | Component | Dose | Duration | Rationale | |-----------|------|----------|----------| | **IV Vancomycin** | 15–20 mg/kg IV BD (target trough 15–20 μg/mL) | 4–6 weeks | Beta-lactam-resistant; bactericidal against MRSA | | **IV Gentamicin** | 3–5 mg/kg IV OD (monitor renal function) | 2 weeks (or full course if complications) | Synergy; enhances bactericidal activity | **Clinical Pearl:** Vancomycin monotherapy is **inadequate** for MRSA IE. Gentamicin must be added for synergy, especially in the first 2 weeks. After 2 weeks, gentamicin can be discontinued if there is clinical improvement and blood cultures are sterilized, but many experts continue it for the full course in complicated IE. ### Why Gentamicin Is Essential 1. **Synergy:** Vancomycin + gentamicin is bactericidal; vancomycin alone is bacteriostatic 2. **Penetration:** Gentamicin improves intracellular and vegetational penetration 3. **Mortality:** Dual therapy reduces mortality compared to monotherapy **Mnemonic: MRSA IE = VG** — **V**ancomycin + **G**entamicin ## Why Other Options Are Wrong | Option | Why Incorrect | |--------|---------------| | IV flucloxacillin + gentamicin | Flucloxacillin is a beta-lactam; MRSA is resistant by definition. This regimen is appropriate for methicillin-*sensitive* S. aureus (MSSA), not MRSA | | Ceftriaxone + rifampicin | Ceftriaxone has limited activity against MRSA. Rifampicin is an adjunctive agent for prosthetic valve IE or intracardiac abscesses, not a primary therapy. This regimen lacks vancomycin and gentamicin | | Vancomycin monotherapy | Monotherapy is insufficient. Gentamicin must be added for synergy. Vancomycin alone is bacteriostatic and associated with higher failure rates and mortality in IE | ## Right-Sided IE Considerations **Clinical Pearl:** Right-sided (tricuspid) IE in IVDU has: - Lower mortality than left-sided IE (if no septic emboli to lungs) - Septic pulmonary emboli (wedge-shaped opacities on CXR) as the hallmark complication - Similar antibiotic regimens but may have better outcomes with medical therapy alone - Surgery reserved for recurrent septic emboli despite appropriate antibiotics, large vegetations (>20 mm), or prosthetic valve involvement This patient's wedge-shaped opacities are **septic pulmonary emboli**, a common feature of right-sided IE. ## Monitoring During Therapy 1. **Vancomycin trough:** Check after 3–5 doses; target 15–20 μg/mL 2. **Gentamicin:** Monitor renal function (risk of nephrotoxicity); measure peak/trough if renal impairment develops 3. **Blood cultures:** Repeat at 48 h to confirm sterilization 4. **Repeat echo:** At 4 weeks to assess vegetation size and valve function [cite:Harrison 21e Ch 124]